BRIDGEBIO PHARMA INC (BBIO) Stock Analyst Ratings
NASDAQ:BBIO • US10806X1028
66.48 USD
-1.13 (-1.67%)
At close: Feb 27, 2026
66.55 USD
+0.07 (+0.11%)
After Hours: 2/27/2026, 8:00:02 PM
ChartMill assigns a Buy % Consensus number of 85% to BBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 99.16. This target is 49.15% above the current price.
- BBIO was analyzed by 28 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about BBIO.
- In the previous month the buy percentage consensus was at a similar level.
- BBIO was analyzed by 28 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-25 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-25 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-25 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-25 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-02-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2026-01-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-06 | Morgan Stanley | Initiate | Overweight |
| 2025-12-15 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-11 | Bernstein | Initiate | Outperform |
| 2025-11-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-31 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-30 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-30 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-10-30 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-30 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-21 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-12 | UBS | Maintains | Buy -> Buy |
| 2025-09-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
BRIDGEBIO PHARMA INC / BBIO FAQ
Can you provide the average price target for BRIDGEBIO PHARMA INC stock?
28 analysts have analysed BBIO and the average price target is 99.16 USD. This implies a price increase of 49.15% is expected in the next year compared to the current price of 66.48.
Can you provide the consensus rating for BRIDGEBIO PHARMA INC stock?
The consensus rating for BRIDGEBIO PHARMA INC (BBIO) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for BRIDGEBIO PHARMA INC stock?
The number of analysts covering BRIDGEBIO PHARMA INC (BBIO) is 28.